Vita Therapeutics Raises $32 Million in Oversubscribed Series a Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat Muscular Dystrophies

Vita Therapeutics announced the completion of an oversubscribed $32 million Series A. Vita’s lead therapy, VTA-100, is currently undergoing studies for the treatment of limb-girdle muscular dystrophy. It is designed to be an autologous treatment that combines gene correction and iPSC technology to help repair and replace muscle cells.